Nav: Home

Study finds opposing trends in hospitalizations, costs for gout and rheumatoid arthritis

June 07, 2016

While hospitalizations related to rheumatoid arthritis have dropped considerably over the past two decades, hospitalizations primarily associated with gout have increased dramatically. These results of a study described in a research letter in the June 7, 2016 issue of JAMA reflect improved management of rheumatoid arthritis patients and both an increased prevalence and persistent suboptimal care of gout.

"Our findings provide a remarkably encouraging benchmark for the improvement in rheumatoid arthritis care in recent years," says Hyon K. Choi, MD, DrPH, of the MGH Division of Rheumatology, Allergy and Immunology, senior author of the JAMA report. "However, they also highlight the critical need to improve gout management in the U.S. and beyond."

Gout and rheumatoid arthritis are the two most common inflammatory joint disorders worldwide, but long-term data reflecting hospitalizations for these conditions has not been available. Choi explains that such information can improve our understanding of the extent of the conditions and the quality of care provided. To conduct their analysis, he and his colleagues gathered data from the Nationwide Inpatient Sample compiled by the Agency for Healthcare Research and Quality, covering the years 1993-2011. They investigated overall rates of hospitalizations, rates of surgery related to either condition and inflation-adjusted hospital costs.

While the rate of hospitalizations for rheumatoid arthritis dropped by 67 percent - from 13.9 to 4.6 per 100,000 in the U.S. population - the rate for gout doubled from 4.4 to 8.8 per 100,000. Surgical hospitalizations for rheumatoid arthritis dropped by 75 percent from 8.4 to 2.1 per 100,000, whereas those for gout remained practically unchanged (from 0.09 to 0.17 per 100,000). Inflation-adjusted annual costs for rheumatoid arthritis hospitalizations dropped by 33 percent from $83,101 in 1993 to $55,988 per 100,000 in 2011; in the same period inflation-adjusted annual hospitalization costs for gout rose by 68 percent from $34,457 to $58,003.

Choi explains that widespread use of effective medications for rheumatoid arthritis -- including methotrexate and the newer, genetically engineered biologics -- along with better management and earlier treatment, have contributed to a reduced incidence of complications requiring hospitalizations, including those for systemic complications and major joint surgeries. Western lifestyle factors -- including consumption of meats, fats, sugary sodas , and alcohol - and risk factors including obesity, hypertension and chronic kidney disease all contribute to the increased frequency of gout, which now affects more than 8 million in the U.S.

"A recent study found that up to 89 percent of hospitalizations for gout were preventable, owing to inadequate or inefficient care," he explains. "While many patients are candidates for uric-acid-lowering medications, only a small proportion receive treatment. In fact, many physicians are not even measuring uric acid levels for their patients who do receive uric-acid-lowering prescriptions. Most importantly, few patients receive personalized lifestyle advice to reduce risk factors and complications or clear education about the essentially curable nature of this disease. That has led to very poor treatment adherence among patients, with one study finding adherence among gout patients to be the worst among seven chronic conditions."

A professor of Medicine at Harvard Medical School, Choi adds, "Advanced gout can be quite debilitating, as it leads to joint destruction and deformity, and acute gout flares are one of the most painful conditions experienced by humans. The pathogenesis of gout is well understood and effective treatments are available, but the care of gout remains remarkably suboptimal due to a lack of proper patient education and treatment mismanagement."
-end-
The lead author of the JAMA letter is Sian Yik Lim, MD, MGH Division of Rheumatology, Allergy and Immunology. Additional co-authors are Na Lu, MPH, Amar Oza, MD, and Mark Fisher, MD, MPH, MGH Rheumatology, Allergy and Immunology; Mariano Menendez, MD, MGH Department of Orthopædic Surgery, and Sharan Rai, Arthritis Research Canada. The study was supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01 AR065944.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals, earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service and returned to the number one spot on the 2015-16 U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Rheumatoid Arthritis Articles:

Study examines opioid use in patients with rheumatoid arthritis
A new analysis indicates that the use of opioid pain medications in older US rheumatoid arthritis patients peaked in 2010 and is now declining slightly.
Studies examine rheumatoid arthritis patients' prognosis
What's the long-term outlook for today's patients with early rheumatoid arthritis?
Obesity may influence rheumatoid arthritis blood tests
New research reveals that in women, obesity may influence blood tests used to diagnose and monitor rheumatoid arthritis.
New tool for prognosis and choice of therapy for rheumatoid arthritis
In rheumatoid arthritis, antibodies are formed that affect the inflammation in the joints.
The promise of precision medicine for rheumatoid arthritis
In a new study, a Yale-led research team identified the mechanism of a gene that raises the risk of severe rheumatoid arthritis in susceptible individuals.
Immunotherapy reduces cardiovascular risk in rheumatoid arthritis
Weight loss from bariatric surgery appears to reverse the premature aging associated with obesity, according to research presented today at Frontiers in CardioVascular Biology 2016.
Osteoarthritis just as severe as rheumatoid arthritis
Rheumatologists more likely to underestimate clinical status of their OA patients than their RA patients
Serotonin deficiency implicated in rheumatoid arthritis
For the first time, serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of rheumatoid arthritis (RA).
Link between mood, pain in rheumatoid arthritis patients
Depressive symptoms and mood in the moment may predict momentary pain among rheumatoid arthritis patients, according to Penn State researchers.
Inflammation in the mouth and joints in rheumatoid arthritis
Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Sheila Arvikar, Massachusetts General Hospital, Boston, USA, will present a study titled 'Inflammation in the Mouth and Joints in Rheumatoid Arthritis.' The IADR General Session is being held in conjunction with the 44th Annual Meeting of the American Association for Dental Research and the 39th Annual Meeting of the Canadian Association for Dental Research.

Related Rheumatoid Arthritis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...